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The idea
linking adverse side effects with target interaction
Gastrointestinal disorders
Pregnancy, puerperium and perinatal conditions
Infections and infestations
Congenital, familial and genetic disorders
Nervous system disorders
Skin and subcutaneous tissue disorders
Injury, poisoning and procedural complications
Eye disorders
Metabolism and nutrition disorders
Renal and urinary disorders
General disorders and administration site conditions
Reproductive system and breast disorders
Respiratory, thoracic and mediastinal disorders
Cardiac disorders
Endocrine disorders
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Investigations
Psychiatric disorders
Blood and lymphatic system disorders
Immune system disorders
Surgical and medical procedures
Vascular disorders
Musculoskeletal and connective tissue disorders
Social circumstances
Hepatobiliary disorders
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The predecessor technique
Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-
Target Effect From Chemical Structure 
A. Bender, J. Scheiber, M. Glick, JW. Davies, K. Azzaoui,  J. Hamon, L. Urban, S. Whitebread, 
JL. Jenkins. 
ChemMedChem Volume 2, Issue 6, Date: June 11, 2007, Pages: 861-873 
 1 model based on World drug index as data pool 
 Hand-curated terminology 










































































6 | Side effect profile prediction | Josef Scheiber | Aug 19, 2007 | ACS Conference
Key requirement 1: A curated terminology
Immune system disorders
Anaphylactic responses Primary immunodeficiency syndromes
Allergic conditions Anaphylactic shock
Anaphylactic reaction to vaccine
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Key requirement 2: 
Database of chemicals linked with terminology
heartburn 
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Data sources
Compound structures from DrugBank and PubChem
Side effects from Facts & Comparisons 4.0 (WoltersKluwer) 
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Data preparation and modeling
ECFP descriptors
heartburn 
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The outcome: Features linked with targets
 Now, let’ s tie it together!
Features linked with AEs
Example: 
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Targets correlated 
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Showcase: Cerivastatin (Baycol®, Lipobay®)
Hypothesis based on prediction:
Cerivastatin hits JNK2alpha1 
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Showcase: Cerivastatin (Baycol®, Lipobay®)
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Finally …
JNK phosphorylates SMAD 2/3 which also  
  interacts with TGFβ 
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Ok …
Hypothesis based on prediction:
Cerivastatin hits JNK2alpha1 
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But: There’ s no color-blindness with statins
Only when given in 
combination with 
erythromycin, a potent 
inhibitor of statin 
metabolism !
 Bioavailability in eye is 
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Summary
Prediction of AEs and link to targets is established
Model quality can be analyzed and utilized in future work
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Future plans
Incorporate gene expression data to better localize AEs
Identify pathway combinations that cause AEs
Find AE/AE correlations
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The vision: Expanding the knowledge
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from Wikipedia
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But …
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Modeling the DrugBank data
Or: Testing Bayes’  fitness
Multicategory Bayesian modeling in Pipeline Pilot Preferred term 
level
100 different MCM models (each ~ 1700 categories)
Model quality is consistent, 
BUT:




























































































































Direct correlation between 
true and false positives








































No correlation between 
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The consequence
Prefer models with at least a 2:1 TP/FP-rate
Rank models based on their stability
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